Lexeo Therapeutics, Inc. Segments Disclosure
13. Segment Information
The Company's CODM is its . All of the Company’s operating results are reviewed by the Company’s CODM within the same statement of operations and comprehensive loss whether research and development (by program) or general and administrative in nature. Accordingly, the Company has determined that it has a reportable segment and operating segment structure. The Company's CODM regularly reviews total expenses and expenses by significant areas such as departments and programs to make decisions when evaluating the Company's financial performance. The Company does not evaluate performance or allocate resources based on segment asset data and therefore such information is not presented. All long-lived assets are located in the United States.
The following table contains additional information on the Company's net loss, including significant segment expenses for the years ended December 31, 2025 and December 31, 2024:
|
Year Ended December 31, |
|
|||||
|
2025 |
|
|
2024 |
|
||
Research and development expense |
|
|
|
|
|
||
LX2006 |
$ |
18,163 |
|
|
$ |
14,256 |
|
LX2020 |
|
15,413 |
|
|
|
23,451 |
|
LX1001 |
|
1,168 |
|
|
|
4,501 |
|
Other programs |
|
2,075 |
|
|
|
3,424 |
|
Employee compensation expenses |
|
15,183 |
|
|
|
16,010 |
|
Lab-related costs and supplies |
|
1,550 |
|
|
|
1,367 |
|
All other research and development expense |
|
10,245 |
|
|
|
11,082 |
|
General and administrative expense |
|
|
|
|
|
||
Employee compensation expenses |
|
8,461 |
|
|
|
6,685 |
|
All other general and administrative expense |
|
36,999 |
|
|
|
24,990 |
|
Other income and expense, net |
|
(9,296 |
) |
|
|
(7,433 |
) |
Net loss |
$ |
(99,961 |
) |
|
$ |
(98,333 |
) |
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 30, 2026 | Showing above |
| 2024 | Mar 24, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.